bi 1323495
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2018 (NCT03588390)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Elastase 2AINHIBITOR
CELA2A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04656275 | Phase 1 | Jan 25, 2021 | Boehringer Ingelheim |
| NCT04619251 | Phase 1 | Nov 13, 2020 | Boehringer Ingelheim |
| NCT04257032 | Phase 1 | Feb 13, 2020 | Boehringer Ingelheim |
| NCT04107805 | Phase 1 | Oct 14, 2019 | Boehringer Ingelheim |
| NCT04011241 | Phase 1 | Jul 24, 2019 | Boehringer Ingelheim |
| NCT03802331 | Phase 1 | Jan 28, 2019 | Boehringer Ingelheim |
| NCT03588390 | Phase 1 | Jul 31, 2018 | Boehringer Ingelheim |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 7 | 7 | 1 | 2018 |
1 organizations
Page 1 / 1